Merck said on Wednesday a combination of its experimental drug and blockbuster therapy Keytruda failed a late-stage trial ...

Dietary Change Starves Cancer Cells, Overcoming Treatment Resistance Nov. 18, 2022 — A dietary change could be a key to enhancing colon cancer treatment, a new study finds. Researchers found in ...

Merck & Co.’s said a late-stage trial of its blockbuster cancer drug Keytruda in combination with favezelimab failed to meet ...

Yoshiaki Nakamura, MD, PhD, discusses how the use of tissue-free circulating tumor DNA (ctDNA) analysis for detecting minimal residual disease (MRD) can enhance the prediction of recurrence in stage ...

Merck said on Wednesday a combination of its experimental drug and blockbuster therapy Keytruda failed a late-stage trial testing it in previously treated patients with a type of colorectal cancer.

Research has revealed how disruption of the circadian clock, the body's internal, 24-hour biological pacemaker, may accelerate the progression of colorectal cancer by affecting the gut microbiome and ...

Three monoclonal antibodies (cetuximab, bevacizumab and panitumumab) have been approved for the treatment of colorectal cancer in the USA and a large number of other monoclonal antibodies are ...

Medical experts discuss how to frame the conversation with patients about third-line metastatic colorectal cancer treatment ...